Molecule to Market: Inside the outsourcing space

The BioPharmGuy

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Adam Wilson, President - BioPharmGuy. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Adam, covering:

• The humble start-up story and journey of the biopharmguy.
• The pivot that took the website from being a job sharing site to one of the most widely-regarded and used platforms in the biotech world.
• The value of simply focussing on looking after your product as your fundamental market differentiator.
• Poking fun at the sector and being a source of entertainment as well as information.

Adam is the BioPharmGuy. Prior to running BioPharmGuy full-time, he worked as a Process Development Engineer at a public biotech, an FDA Investigator and a Lab Tech in a dermatology research lab at a nonprofit hospital. His various experiences have contributed to his knowledge of the biotech industry which has enabled BioPharmGuy to become the best biotech company directory in existence. He independently created and built BioPharmGuy.com which now receives 40,000+ unique visitors every month.

The website built around a database of information on biotech, pharmaceutical, medical device and life science companies around the world. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed. Your host Raman Sehgal is the author of The Floundering Founder.

Chronicles of Swiss Biotech day

Event season is truly well on its way and where better to start than Swiss Biotech Day, the leading biotechnology conference in Switzerland. Renowned for its innovative biotech start-ups and big pharma companies all in attendance, it was a great chance to meet experts from the life science industry from across Europe. Which is why it should come as no surprise that your host Raman Sehgal brought Molecule to market once more to the event space.

If you loved the ‘Memoir of DCAT 2022’ episode, this is a pod for you as he hit the event space again in style and interviewed some more great guests along the way. Listen to a diverse range of our guests’ thoughts during this event.

• Richard Collins, Managing Director Bio2Business Ltd
• Hanns-Christian Mahler, CEO at ten23 health
• Stefano Console, Founder & Senior Advisor at Oriento SA
• Philippe Tschopp, Head of Business Development CDMO Glatt

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed.

From CDMO builder to CDMO creator

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Terry Novak, President & Chief Executive Officer at Salubrent Pharma Solutions. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Terry, covering:

• What he has learnt from 40 years in the pharma, biopharma and contract services space
• The best marketing technique - communicating constantly to your internal audience.
• The wave of orphan drugs that are driving demand for small scale and flexible manufacturing capabilities.
• How a focus on talent is going to make or break companies in the next 3-5 years.

Terry has extensive CDMO C-suite execution experience serving in numerous capacities. Terry has served on the Board of Directors of Pernix Therapeutics Ireland, Percivia LLC, American Red Cross Northern NJ Division, Patheon Puerto Rico, Frontline Pharmaceuticals, Curaxis Pharmaceuticals and is currently on the Board of Directors of Salubrent Pharma Services and Minutemen Life Sciences. Operationally, Terry has served as the CEO of Tedor Pharmaceuticals, COO of Pernix Pharma, President of Norwich Pharmaceuticals, President of Patheon North America, President of Frontline Pharmaceuticals and President of DSM.

During his 40 years in industry, he had built a track record of rapid turn-around success includes achieving consistent double-digit growth in revenues and EBITDA.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

Built in Boston, now rebuilding businesses

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Michael Kallelis, Chief Executive Officer at Mikart.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Mike, covering:

• Growing up, studying and forging a career in Boston during the volatile biotech boom in Massachusetts.
• His hard-earned 40-years playbook of how to rebuild and revitalise a family owned business by respecting, studying and redirecting efforts.
• An insight into the under the radar but explosively vibrant life science scene in Atlanta, GA
• The role of a mid-market CDMO to drug development companies.
• The phenomenon hitting the North America healthcare market that you need to be aware of as it will impact CDMOs in the small molecule space...

Michael Kallelis has spent his career in public and private life science companies where he has successfully implemented commercial and operational growth strategies. Prior to Mikart, he held several senior roles including president of Exiqon Inc., co-founder and chief operating officer of Boston Biosystems, vice president of business development at KMC Systems, and general manager of several GE Healthcare businesses. 

His experience covers a range of technologies, including radiopharmaceuticals, gene expression analysis, medical devices, automated laboratory systems, oligonucleotides, specialty chemicals, biologics, and small molecules. Mike has been the CEO at Mikart since the fall of 2018.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed.

In the trenches of pharma manufacturing

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Ray Kaczmarek, Chief Executive Officer at Genezen. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Ray, covering:

• Translating military life lessons into key business leadership - taking care of your people, having operational discipline and allowing people to be leaders.
• Invaluable learnings from taking a drug from clinical trials to commercial and on-market supply.
• Insight into the booming cell and gene therapy space and how it will change the way we view medicine as a cure, not a treatment.
• The under the radar, up and coming region of Fishers, Indianapolis. Could this be the next big life science hub?

Genezen CEO Ray has over 25 years of leadership experience with the past 20 years in biotechnology and pharmaceutical operations. Ray has previously held positions including President at Nitto Avecia Pharma Services, Founder OC Biotech Consultants, SVP of GMP Operations at TriLink BioTechnologies, and VP of Manufacturing and Supply Chain Operations at Pacira Biosciences. He has supported new drug development, clinical operations, and commercial operations in biologics, vaccines, and pharmaceuticals throughout his career. Ray leads Genezen’s growth strategy and is focused on finding ways to achieve excellence for our employees, our clients, and their patients.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

From Sweden with Science

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Hans J Johansson, Global Applications Director at Purolite. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Hans, covering:

• A career spent developing ideas and creating products that produce new applications for customers and commercial success.
• Driving the Purolite business unit from the ground-up from a lab bench to a commercial scale life science based franchise.
• Hans’ lifelong habits and approach that have enabled him to have a successful career.
• An insight into Sweden’s vibrant life science hub - Uppsala.
• The development of new technologies that will increase yield while reducing environmental footprint... a sign of things to come!

Hans J Johansson is Global Applications Director at Purolite Life Sciences, Llantrisant, Wales. He has spent more than 30 years in the Biotech industry. Most of the time in research and development at Pharmacia/Amersham/GE Healthcare with a special focus on design and applications of industrial chromatography resins intended for antibody purification. He frequently publishes in scientific journals and is the holder of more than ten patents around resin design and large-scale protein purification. He is currently working with development and applications of novel, agarose-based, chromatography resins.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

The niche, niche CDMO with enviable patient reach

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Jim Hall, President at Lifecore Biomedical

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Jim, covering: 

• What a period working on the sponsor/buyer side taught him about getting best out of your CROs and CDMOs

• The challenges of doubling in size twice in just 10 years and not getting ‘too far out over your skis’
• Building a culture with longevity and not losing sight of the purpose - never hurting a patient
• Insight into market growth figures and why the injectable market remains a hot spot
• Timeless advice around not chasing the money, always be learning and keeping an open mind

Jim was appointed President in June 2017. He served as Vice President and General Manager since July 2013, Vice President of Operations since 2006 and was Director of Manufacturing Operations and Engineering since 2001; prior to that he was the Manager of Engineering and Operations at Lifecore. Mr. Hall brings over 30 years of pharmaceutical and combination product manufacturing and development experience.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed.

Diaries of DCAT

Last week marked the return of DCAT in New York City. A prestigious event that’s open to companies engaged in the Biotech and Pharmaceutical manufacturing space…

With the massive return this year of events. Your host, Raman Sehgal, decided to shake things up this year and do things differently, taking your favourite life science podcast Molecule to market with him… Equipped with only a laptop and a microphone, he hit the event space in style and interviewed some great guests along the way.

Listen to a variety of select guests at the top of their field. 

• Yasmin Davoodi, Head Of Commercial at ramarketing

• Jon Lenihan, Head of Sales & Business Development, CDMO Business Unit Head at Emergent Biosolutions

• David Enloe, President and CEO of Societal™ CDMO (formerly Recro)

• Gil Roth, President, Pharma and Biopharma Outsourcing Association

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed.

Finland’s Viral Vector Manufacturer of Happinesses

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Magnus Gustafsson, formerly at the time of recording Head of Global Business Development now Chief Business Officer at Biovian.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Magnus, covering:

• The advantages and disadvantages of viral vector products, including the challenge of needing to balance cost with patient access.

• Insights into a CDMO with a 96% staff retention rate and an enviable NPS score.

• The ballooning opportunity that exists in the viral vector space but also the risk that potentially comes along with such a popular platform.

• What makes Finland and the Nordic region so special?

Magnus Gustafsson has worked in the biopharma manufacturing space for over 20 years. He holds an MSc in Biochemical Engineering, an MBA in Business Administration and a PhD in Medical Protein Science. Having worked for the likes of AZ, GE, Recipharm and Cobra Biologics, he has a track record of driving business with both commercial and strategic success combined with a customer-centric mindset. 

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed.

From corporate rebel to CDMO entrepreneur

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Hanns-Christian Mahler CEO at ten23 health.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Hanns, covering:

• Transitioning from the structure and scale of Merck, Roche and Lonza into an entrepreneurial start-up CDMO leader.
• Having a business purpose focused on the triple-bottom line that is not just profit - patients, people and planet.
• Tips and insights of how a CDMO can play its part in encouraging sustainability, reducing environmental impact and managing footprints, across all levels.
• Insights into the opportunity and growth in small-scale sterile biologics, and some of the drivers behind these trends.
• Dr. Mahler is CEO & Board Member at ten23 health. He previously led the Drug Product Services (DPS) Business Unit at Lonza and worked in various leadership roles at Roche and Merck. He has an extensive expertise in formulation development, process development & validation, packaging/device development and integration, sterile manufacturing, and regulatory submissions.

With a Ph.D. in toxicology, he also serves as Editor for Pharmaceutical Research, Journal of Pharmaceutical Sciences, AAPS Open Journal, and PDA Journal of Pharmaceutical Sciences & Technology. He has published more than 120 manuscripts and is co-inventor of more than 50 patents.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed.